- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Protein synthesis.
Displaying page 1 of 1.
EudraCT Number: 2015-002567-42 | Sponsor Protocol Number: 5A | Start Date*: 2015-07-15 |
Sponsor Name:Stockholm County Council, Karolinska University Hospital Huddinge, Dept of Anesthesiology and Intensive Care | ||
Full Title: Predictors of albumin synthesis rate in severe liver failure. An open exploratory study in patients with chronic liver failure assessed for liver transplantation | ||
Medical condition: Severe chronic liver failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002568-18 | Sponsor Protocol Number: 5B | Start Date*: 2015-07-15 |
Sponsor Name:Stockholm County Council, Karolinska University Hospital Huddinge, Department of Anesthesiology and Intensive Care | ||
Full Title: Albumin mass balance and kinetics in liver transplantation. An open exploratory pilot study | ||
Medical condition: liver transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003750-10 | Sponsor Protocol Number: NA | Start Date*: 2005-09-12 |
Sponsor Name:VästraGötaland | ||
Full Title: Growth hormone and androgens in the treatment of glucocorticoid induced protein catabolism | ||
Medical condition: Chronic treatment with glucocorticoids (GCs) regardless of indication leads to marked protein catabolism that causes substantial debilitation which includes muscle wasting, weakness, skin fragility... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001528-37 | Sponsor Protocol Number: Cholzuur | Start Date*: 2020-04-09 |
Sponsor Name:Cbusinez | ||
Full Title: Long-term safety study of personalized magistral prepared cholic acid capsules in patients with bile acid synthesis defects | ||
Medical condition: Patients with phenotypically mild Zellweger Spectrum Disorder (ZSD) or a Single Enzyme Defect (SED) in bile acid synthesis. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004528-36 | Sponsor Protocol Number: CAC-002-01 | Start Date*: 2011-10-06 | |||||||||||
Sponsor Name:Asklepion Pharmaceuticals, LLC | |||||||||||||
Full Title: An open-label, single center, non-randomized, continuation study of cholic acid capsules in subjects with inborn errors of bile acid synthesis. | |||||||||||||
Medical condition: Patients with inborn errors of bile acid synthesis and metabolism | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006948-65 | Sponsor Protocol Number: Version 4 | Start Date*: 2007-11-29 |
Sponsor Name:University Hospitals of Leicester NHS Trust | ||
Full Title: The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients | ||
Medical condition: Chronic kidney disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000051-24 | Sponsor Protocol Number: RemiPedEntropy_v1.0 | Start Date*: 2015-03-26 |
Sponsor Name:Klaus Olkkola/University of Helsinki | ||
Full Title: The pharmacokinetics and –genomics of remifentanil, and its effects on the depth-of-anaesthesia monitors and the protein synthesis in children. | ||
Medical condition: otherwise healthy patients undergoing an operation necessitating general anaesthesia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005534-12 | Sponsor Protocol Number: AVH-2004/1 | Start Date*: 2006-04-18 |
Sponsor Name:The Symbio Herborn Group GmbH | ||
Full Title: randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy | ||
Medical condition: Allergic diseases such as rhinoconjunctivitis or bronchial asthma are a major public health burden. The huge associated costs demand an evidence based therapeutic aproach. The only available causat... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005979-16 | Sponsor Protocol Number: PrOvAS001 | Start Date*: 2013-04-29 |
Sponsor Name:Instituto de Investigación Sanitaria La Fe | ||
Full Title: PREECLAMPSIA OF PREVENTION IN PATIENTS THROUGH ovodonation aspirin in early gestation | ||
Medical condition: PREECLAMPSIA | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001560-14 | Sponsor Protocol Number: FJD-RA-TOF-60418809 | Start Date*: 2021-08-13 |
Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE | ||
Full Title: Single-center, open-label, uncontrolled clinical trial to evaluate the association between the expression of the JAK / STAT pathway and the response to tofacitinib in patients with refractory rheum... | ||
Medical condition: Refractory rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004882-26 | Sponsor Protocol Number: ND-L02-s0201-002 | Start Date*: 2015-03-25 | |||||||||||
Sponsor Name:Nitto Denko Corporation | |||||||||||||
Full Title: A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity and Pharmacokinetics of ND L02 s0201 Injection, a Vitamin A-couple... | |||||||||||||
Medical condition: Moderate to extensive progressive hepatic fibrosis (METAVIR F3-4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001635-21 | Sponsor Protocol Number: VIA-2291-02 | Start Date*: 2006-12-21 | |||||||||||
Sponsor Name:VIA PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A Phase 2 Randomised, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients wi... | |||||||||||||
Medical condition: Carotid Stenosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002638-35 | Sponsor Protocol Number: 3.00 | Start Date*: 2012-07-31 |
Sponsor Name:Stockholms Läns Landsting, Karolinska Universitetssjukhuset Huddinge, Anestesikliniken | ||
Full Title: ALBUMIN KINETICS BY 123I-HSA A validation study on healthy volunteers, patients with acute inflammation, and patiens scheduled for major abdominal surgery | ||
Medical condition: A) healthy volunteers (transcapillary escape rate of albumin, plasmavolume, and turnover of albumin) B) Acute inflammation such as pancreatitis or cholecystitis C) Scheduled major abdominal surge... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016703-35 | Sponsor Protocol Number: NAPMSv3.2 | Start Date*: 2010-01-08 | ||||||||||||||||
Sponsor Name:Dansk Multipel Sclerose Center | ||||||||||||||||||
Full Title: Natalizumabbehandling af progressiv multipel sklerose | ||||||||||||||||||
Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004565-14 | Sponsor Protocol Number: ECP-002e | Start Date*: 2014-02-13 | |||||||||||
Sponsor Name:Edimer Pharmaceuticals, Inc. | |||||||||||||
Full Title: Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002 | |||||||||||||
Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1.... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022046-25 | Sponsor Protocol Number: Zellweger | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Department of Pediatric Gastroenterology, Academic Medical Centre | ||||||||||||||||||
Full Title: Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. | ||||||||||||||||||
Medical condition: Peroxisomal biogenesis disorder Synonym: Zellweger spectrum disorder This syndrome encompasses a spectrum of severity in symptoms Previously the disorder was subdivided into three disorders based... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003561-17 | Sponsor Protocol Number: ECP-002 | Start Date*: 2013-08-09 | |||||||||||
Sponsor Name:Edimer Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 open-label, dose-escalation study to evaluate the safety, pharmacokinetics, immunogeniticy and pharmacodynamics/efficacy of EDI200, an EDA-A1 replacement protein, administered to male inf... | |||||||||||||
Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1.... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001169-33 | Sponsor Protocol Number: SAFA-1-2012 | Start Date*: 2012-07-02 | ||||||||||||||||
Sponsor Name:Department of Medical Research | ||||||||||||||||||
Full Title: Effects of tolvaptan on renal sodium and water handling and circulation during inhibition of the nitric oxide system in healthy subjects | ||||||||||||||||||
Medical condition: SIADH (Syndrome of inappropriate ADH production) Overhydration Hyponatrimia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004941-34 | Sponsor Protocol Number: GFT505B-319-1 | Start Date*: 2020-10-09 | |||||||||||
Sponsor Name:IPSEN Pharma SAS | |||||||||||||
Full Title: A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Ina... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002120-33 | Sponsor Protocol Number: HLSCS01-11 | Start Date*: 2013-12-06 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA | ||||||||||||||||||||||||||||
Full Title: Human Liver Stem Cells (HLSCs) in patients suffering from liver-based inborn metabolic diseases causing life-threatening neonatal onset of hyperammonemic encephalopathy | ||||||||||||||||||||||||||||
Medical condition: neonatal hyperammonemic encephalopathy associated with inborn liver metabolic diseases | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
